CLZR Candela Corporation featured news, full reports, and detailed charts
Candela Corporation (CLZR) Wrap Up:
Candela Corporation (“Candela” or the “Company”) is a pioneer in the development and commercialization of advanced aesthetic laser and light-based systems that allow physicians and personal care practitioners to treat a wide variety of cosmetic and medical conditions including: † permanent hair reduction on all skin types; † skin rejuvenation, skin tightening and wrinkle reduction; † vascular lesions such as rosacea, facial spider veins, leg veins, port wine stains, angiomas and hemangiomas; † all-color tattoo removal; skin resurfacing scars, stretch marks and warts; † removal of benign pigmented lesions such as sun spots, age spots, freckles, and Nevus of Ota/Ito; † acne and acne scars; † sebaceous hyperplasia; † beard bumps (PFB); † psoriasis; and, † other cosmetic skin treatments. Since our founding 37 years ago, we have continuously developed and enhanced applications for laser and light-based technology. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2007%2f09%2f13%2f0001104659-07-068928.html#FIS_BUSINESS"Candela Corporation (CLZR:NASDAQ)
Snapshot of Candela Corporation (CLZR)
|
OPEN
$2.93
|
PREVIOUS CLOSE
$2.95
|
|
|
DAY HIGH
$2.95
|
DAY LOW
$2.87
|
|
|
52 WEEK HIGH
11/5/09 - $3.55
|
52 WEEK LOW
03/9/09 - $0.27
|
|
|
MARKET CAP
66.2M
|
AVERAGE VOLUME 3 mo
127.9K
|
|
|
DILUTED EPS TTM
$-0.47
|
SHARES OUTSTANDING
22.9M
|
|
|
CLZR Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
CLZR Top Compensated Officers
Executives, Board Directors
Key developments for Candela Corporation (CLZR)
Candela Corp. reported unaudited consolidated earnings results for the first quarter ended September 26, 2009. The company reported that revenues for the quarter ended September 26, 2009 were $26.2 million compared to $26.665 million for the same period of last year. Net loss for the quarter was $3,627,000 or $0.16 per basic and diluted share compared to net loss of $4,009,000 or $0.18 per basic and diluted share for the same period of last year. The current quarter results include approximately $2.3 million of expenses related to merger efforts. The company reported loss from operations of $4.864 million, loss from continuing operations before income taxes of $4.644 million and loss from continuing operations of $3.584 million or $0.16 per basic and diluted share compared to loss from operations of $6.531 million, loss from continuing operations before income taxes of $6.605 million and loss from continuing operations of $3.519 million or $0.16 per basic and diluted share for the same period of last year.
Candela Corp. expected to Report Q2 2010 Results on January 18, 2010. This event was calculated by Capital IQ (Created on October 20, 2009).
Holzer Holzer & Fistel, LLC announced a shareholder class action lawsuit has been filed against Candela Corp. and certain of its directors alleging violations of state law in connection with the buyout of the company by Syneron Medical Ltd. According to the complaint, Candela shareholders will receive 0.2911 shares of Syneron in exchange for each Candela share they own. The complaint alleges Candela's directors breached their fiduciary duty by approving the buyout for inadequate consideration. Further, the complaint alleges Candela's directors breached their fiduciary duties by failing to employ an adequate process to evaluate the transaction.
CLZR Competitors
| Company | Last | Change |
| Cutera Inc | $9.08 USD | +0.02 |
| Cynosure Inc | $10.06 USD | +0.07 |
| IRIDEX Corp | $2.79 USD | +0.01 |
| Solta Medical Inc | $2.24 USD | -0.03 |
| Spectranetics Corp | $6.01 USD | +0.16 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | CLZR | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 0.6x |
|
| Price/Book | 0.9x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 0.3x |
|
|
CLZR |
||
CLZR transactions
| Type Date |
Target |
|
Merger/Acquisition
September 8, 2009 |
-- |
